Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.55 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | PAM | P19021 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8051693 | 0.93 | NR1H4 (0.51) | MEN1KMT2ALTB4RLTB4R2NR1H4 | |
| SCHEMBL137417 | 0.91 | MAOB (0.54) | MEN1KMT2ALTB4RLTB4R2NR1H4 | |
| SCHEMBL136471 | 0.91 | MAOB (0.54) | MEN1KMT2ALTB4RLTB4R2NR1H4 | |
| SCHEMBL491380 | 0.91 | PPARG (0.51) | MEN1KMT2ALTB4RLTB4R2NR1H4 | |
| SCHEMBL491321 | 0.91 | NR1H4 (0.49) | MEN1KMT2ALTB4RLTB4R2NR1H4 | |
| SCHEMBL1008116 | 0.90 | LTB4R (0.61) | LTB4RLTB4R2NR1H4L3MBTL1ALDH1A1 | |
| SCHEMBL18179855 | 0.89 | ALDH1A1 (0.69) | MEN1KMT2ALTB4RLTB4R2L3MBTL1 | |
| SCHEMBL477990 | 0.88 | LTB4R (0.46) | MEN1KMT2ALTB4RLTB4R2NR1H4 | |
| SCHEMBL136924 | 0.87 | RXRA (0.47) | LTB4RLTB4R2NR1H4L3MBTL1ALDH1A1 | |
| SCHEMBL1203178 | 0.87 | ALOX5 (0.67) | LTB4RLTB4R2NR1H4L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393870-B2 | 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20060074116-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-04-06 | — | — | US | disclosed |
| US-7005444-B2 | 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-20030130328-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6559173-B1 | organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | ALLERGAN, INC. | 2003-05-06 | — | — | US | disclosed |
| WO-2003026650-A1 | 3-(HETEROARYLAMINO)METHYLENE-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-0538416-B1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4 ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0538416-A4 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1994-05-18 | — | — | EP | disclosed |
| US-5232948-A | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1993-08-03 | — | — | US | disclosed |
| EP-0538416-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY. | RHONE POULENC RORER INT (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992004315-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074116-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | MEN1 2681/4885KMT2A 1007/4885LTB4R 3579/4885 |
| US-20030130328-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | MEN1 2681/4885KMT2A 1007/4885LTB4R 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.